3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Hepatocellular
2
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Hepatitis, Chronic
1
Hepatitis C
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
BRCA1/2 Mutation
1
Interventions
Fluorouracil
71
pembrolizumab
62
Bevacizumab
60
Oxaliplatin
59
Cetuximab
59
Leucovorin
56
Irinotecan
55
Capecitabine
31
Nivolumab
23
Gemcitabine
18
Cisplatin
18
IFL protocol
17
Folfox protocol
17
Cyclophosphamide
16
Carboplatin
15
atezolizumab
14
Specimen Handling
14
Paclitaxel
14
Magnetic Resonance Spectroscopy
14
Biopsy
14
trifluridine tipiracil drug combination
12
Pemetrexed
10
spartalizumab
9
regorafenib
9
fludarabine
9
Panitumumab
9
130-nm albumin-bound paclitaxel
9
trametinib
8
durvalumab
8
dehydroftorafur
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Colorectal Neoplasms
×
rocakinogene sifuplasmid
×
Clear all
NCT02960594
2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1
Completed
93 enrolled